Altered Reward Circuitry in the Norepinephrine Transporter Knockout Mouse

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Gallagher, Joseph J ^a   Zhang, Xiaowei ^a   Hall, F Scott ^c   Uhl, George R ^c   Bearer, Elaine L ^a,b   Jacobs, Russell E ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; MANGANESE; N ACETYLASPARTIC ACID; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; CAPSULA INTERNA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE DELETION; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NEUROANATOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PREFRONTAL CORTEX; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REWARD; WILD TYPE;

ANIMALS; ASPARTIC ACID; BRAIN; BRAIN MAPPING; CONTRAST MEDIA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; INJECTIONS, INTRAVENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE; MICE; MICE, KNOCKOUT; NEURONS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; REWARD; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOTAXIC TECHNIQUES; SYNAPTIC TRANSMISSION;

EID: 84874613391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057597     Document Type: Article

References (118)

1. Ordway GA, Klimek V, Mann JJ (2002) Neurocircuitry of Mood Disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology -5th Generation of Progress. Philadelphia: Lippincott, Williams, & Wilkins. 1051-1064.
2. Nestler E, Hyman S, Malenka RC (2008) Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Second Edition. New York: McGraw Hill Medical. 516 p.
3. Carson RP, Robertson D, (2002) Genetic manipulation of noradrenergic neurons. J Pharmacol Exp Ther 301: 410-417.
4. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, et al. (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283: 397-401.
5. Wang YM, Xu F, Gainetdinov RR, Caron MG, (1999) Genetic approaches to studying norepinephrine function: Knockout of the mouse norepinephrine transporter gene. Biological Psychiatry 46: 1124-1130.
6. Amara SG, Sonders MS, (1998) Neurotransmitter transporters as molecular targets for addictive drugs. Drug and Alcohol Dependence 51: 87-96.
7. Zhou J, (2004) Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29: 1235-1244.
8. Carboni E, Tanda GL, Frau R, Dichiara G, (1990) Blockade of the Noradrenaline Carrier Increases Extracellular Dopamine Concentrations in the Prefrontal Cortex - Evidence That Dopamine Is Taken up Invivo by Noradrenergic Terminals. Journal of Neurochemistry 55: 1067-1070.
9. Yamamoto BK, Novotney S, (1998) Regulation of extracellular dopamine by the norepinephrine transporter. Journal of Neurochemistry 71: 274-280.
10. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT, (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: Evidence from knock-out mouse lines. Journal of Neuroscience 22: 389-395.
11. Yamashita M, Fukushima S, Shen HW, Hall FS, Uhl GR, et al. (2006) Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout mice. Neuropsychopharmacology 31: 2132-2139.
12. Arime Y, Kasahara Y, Hall FS, Uhl GR, Sora I (2012) Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in animal models of schizophrenia. Neuropsychopharmacology In Press.
13. Caron MG, (1999) Genetic targeting of catecholamine transporters reveal essential roles in neuromodulation, maintenance of homeostasis and psychostimulant action. Biological Psychiatry 45: 5S-6S.
14. Gainetdinov RR, Caron MG, (2003) Monoamine transporters: From genes to behavior. Annual Review of Pharmacology and Toxicology 43: 261-284.
15. Hall FS, Sora I, Drgonova J, Li X-F, Goeb M, et al. (2004) Molecular Mechanisms Underlying the Rewarding Effects of Cocaine. Annals of the New York Academy of Sciences 1025: 47-56.
16. Torres GE, Caron MG, (2005) Approaches to identify monoamine transporter interacting proteins. Journal of Neuroscience Methods 143: 63-68.
17. Hall FS, Schwarzbaum JM, Perona MTG, Templin JS, Caron MG, et al. (2011) A Greater Role for the Norepinephrine Transporter than the Serotonin Transporter in Murine Nociception. Neuroscience 175: 315-327.
18. Arime Y, Hall S, Uhl G, Sora I, (2010) Prefrontal Norepinephrine Transporter Blockade Ameliorates Deficits of Prepulse Inhibition in Dopamine Transporter Knockout Mice via Cortico-subcortical Glutamate Projections. International Journal of Neuropsychopharmacology 13: 59-59.
19. Hall FS, Li XF, Randall-Thompson J, Sora I, Murphy DL, et al. (2009) Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and 5-HT transporter knockout mice. Neuroscience 162: 870-880.
20. Hall FS, Perona MT, Waters S, Sora I, Lesch KP, et al. (2006) The effects of DAT, SERT and NET gene knockout on behavior in animal models of depression. Neuropsychopharmacology 31: S155-S156.
21. Dar DE, Metzger TG, Vandenbergh DJ, Uhl GR, (2006) Dopamine uptake and cocaine binding mechanisms: The involvement of charged amino acids from the transmembrane domains of the human dopamine transporter. European Journal of Pharmacology 538: 43-47.
22. Perona MTG, Waters S, Hall FS, Sora I, Lesch KP, et al. (2008) Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behavioural Pharmacology 19: 566-574.
23. Homberg J, van der Marel K, Otte W, Olivier J, van der Hart M, et al. (2008) In vivo recording of cocaine-induced brain activity using pharmacological MRI in the serotonin transporter knockout rat: A bridge to the human serotonin transporter polymorphism and its impact on cocaine dependence? Behavioural Pharmacology 19: S21.
24. Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, et al. (2003) Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. Journal of Neurochemistry 84: 1256-1265.
25. Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, et al. (2007) Methamphetamine-induced hyperthermia and lethal toxicity: Role of the dopamine and serotonin transporters. European Journal of Pharmacology 572: 120-128.
26. Ikemoto S, (2007) Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Research Reviews 56: 27-78.
27. Medvedev IO, Gainetdinov RR, Sotnikova TD, Bohn LM, Caron MG, et al. (2005) Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology 180: 408-413.
28. Mead AN, Rocha BA, Donovan DM, Katz JL, (2002) Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine-, but not dopamine-transporter knockout mice. European Journal of Neuroscience 16: 514-520.
29. Jones JD, Hall FS, Uhl GR, Riley AL, (2010) Dopamine, norepinephrine and serotonin transporter gene deletions differentially alter cocaine-induced taste aversion. Pharmacology Biochemistry and Behavior 94: 580-587.
30. Perles-Barbacaru T-A, Procissi D, Demyanenko AV, Hall FS, Uhl GR, et al. (2011) Quantitative pharmacologic MRI: Mapping the cerebral blood volume response to cocaine in dopamine transporter knockout mice. Neuroimage 55: 622-628.
31. Sora I, Hall FS, Andrews AM, Itokawa M, Li XF, et al. (2001) Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proceedings of the National Academy of Sciences of the United States of America 98: 5300-5305.
32. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, et al. (1998) Cocaine self-administration in dopamine-transporter knockout mice. Nature Neuroscience 1: 132-137.
33. Dykstra LA, Bohn LM, Rodriguiz RM, Wetsel WC, Gainetdinov RR, et al. (2003) Rewarding properties of cocaine in dopamine/norepinephrine transporter knockout mice. Faseb Journal 17: A205-A205.
34. Solich J, Faron-Gorecka A, Kusmider M, Palach P, Gaska M, et al. (2011) Norepinephrine transporter (NET) knock-out upregulates dopamine and serotonin transporters in the mouse brain. Neurochemistry International 59: 185-191.
35. Woo KV, Walker JKL, Bohn LM, Caron MG, Rockman HA, (2001) Norepinephrine transporter knockout: Its effect on the central nervous system and exercise function. Circulation 104: 173-173.
36. Haller J, Bakos N, Rodriguiz RM, Caron MG, Wetsel WC, et al. (2002) Behavioral responses to social stress in noradrenaline transporter knockout mice: Effects on social behavior and depression. Brain Research Bulletin 58: 279-284.
37. Keller NR, Diedrich A, Appalsamy M, Tuntrakool S, Lonce S, et al. (2004) Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation 110: 1191-1196.
38. Vizi ES, Zsilla G, Caron MG, Kiss JP, (2004) Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: Implications for the action of selective serotonin reuptake inhibitors. Journal of Neuroscience 24: 7888-7894.
39. Dzirasa K, Phillips HW, Sotnikova TD, Salahpour A, Kumar S, et al. (2010) Noradrenergic Control of Cortico-Striato-Thalamic and Mesolimbic Cross-Structural Synchrony. Journal of Neuroscience 30: 6387-6397.
40. Bearer EL, Zhang X, Janvelyan D, Boulat B, Jacobs RE, (2009) Reward circuitry is perturbed in the absence of the serotonin transporter. Neuroimage 46: 1091-1104.
41. Zhang X, Bearer EL, Boulat B, Hall FS, Uhl GR, et al. (2010) Altered Neurocircuitry in the Dopamine Transporter Knockout Mouse Brain. PLoS ONE 5: e11506.
42. Wolf ME, (2002) Addiction: Making the Connection Between Behavioral Changes and Neuronal Plasticity in Specific Pathways. Molecular Interventions 2: 146-157.
43. Sesack SR, Grace AA, (2010) Cortico-Basal Ganglia Reward Network: Microcircuitry. Neuropsychopharmacology Reviews 35: 27-47.
44. Koob GF, Volkow ND, (2010) Neurocircuitry of Addiction. Neuropsychopharmacology 35: 217-238.
45. Haber SN, Calzavara R, (2009) The cortico-basal ganglia integrative network: The role of the thalamus. Brain Research Bulletin 78: 69-74.
46. Silva AC, Lee JH, Aoki I, Koretsky AP, (2004) Manganese-enhanced magnetic resonance imaging (MEMRI): methodological and practical considerations. NMR in Biomedicine 17: 532-543.
47. Murayama Y, Weber B, Saleem KS, Augath M, Logothetis NK, (2006) Tracing neural circuits in vivo with Mn-enhanced MRI. Magnetic Resonance Imaging 24: 349-358.
48. Eschenko O, Canals S, Simanova I, Logothetis NK, (2010) Behavioral, electrophysiological and histopathological consequences of systemic manganese administration in MEMRI. Magnetic Resonance Imaging 28: 1165-1174.
49. Rudin M, Beckmann N, Mir A, Sauter A, (1995) In-vivo magnetic-resonance-imaging and spectroscopy in pharmacological research - assessment of morphological, physiological and metabolic effects of drugs. Eur J Pharm Sci 3: 255-264.
50. Brian Ross SB, (2001) Magnetic resonance spectroscopy of the human brain. The Anatomical Record 265: 54-84.
51. Valenzuela MJ, Sachdev P, (2001) Magnetic resonance spectroscopy in AD. Neurology 56: 592-598.
52. Lyoo IK, Renshaw PF, (2002) Magnetic resonance spectroscopy: Current and future applications in psychiatric research. Biological Psychiatry 51: 195-207.
53. Marjanska M, Curran GL, Wengenack TM, Henry P-G, Bliss RL, et al. (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proceedings of the National Academy of Sciences 102: 11906-11910.
54. Meyer JS, Brevard ME, Piper BJ, Ali SF, Ferris CF (2006) Neural effects of MDMA as determined by functional magnetic resonance imaging and magnetic resonance spectroscopy in awake marmoset monkeys. Cellular and Molecular Mechanisms of Drugs of Abuse and Neurotoxicity: Cocaine, Ghb, and Substituted Amphetamines. Oxford: Blackwell Publishing. 365-376.
55. Pouwels PJW, Frahm J, (1998) Regional Metabolite Concentrations in Human Brain as Determined by Quantitative Localized Proton MRS. Magn Reson Med 39: 53-60.
56. Tkac I, Henry P-G, Andersen P, Keene CD, Low WC, et al. (2004) Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. Magnetic Resonance in Medicine. 52: 478-484.
57. Sanacora G, Rothman D, Krystal JH, (1999) Applications of Magnetic Resonance Spectroscopy to Psychiatry. Neuroscientist 5: 192-196.
58. Lau JC, Lerch JP, Sled JG, Henkelman RM, Evans AC, et al. (2008) Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. NeuroImage 42: 19-27.
59. Hua X, Hibar DP, Lee S, Toga AW, Jack CR, et al. (2010) Sex and age differences in atrophic rates: an ADNI study with n = 1368 MRI scans. Neurobiology of Aging 31: 1463-1480.
60. Ottobrini L, Martelli C, Trabattoni D, Clerici M, Lucignani G, (2011) In vivo imaging of immune cell trafficking in cancer. European Journal of Nuclear Medicine and Molecular Imaging 38: 949-968.
61. Getts DR, Martin AJ, McCarthy DP, Terry RL, Hunter ZN, et al. (2012) Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotech 30: 1217-1224.
62. Jokerst JV, Gambhir SS, (2011) Molecular Imaging with Theranostic Nanoparticles. Accounts of Chemical Research 44: 1050-1060.
63. Bossa M, Zacur E, Olmos S, (2010) Tensor-based morphometry with stationary velocity field diffeomorphic registration: Application to ADNI. Neuroimage 51: 956-969.
64. Koikkalainen J, Lötjönen J, Thurfjell L, Rueckert D, Waldemar G, et al. (2011) Multi-template tensor-based morphometry: Application to analysis of Alzheimer's disease. Neuroimage 56: 1134-1144.
65. Narayana PA, Datta S, Tao G, Steinberg JL, Moeller FG, (2010) Effect of cocaine on structural changes in brain: MRI volumetry using tensor-based morphometry. Drug and Alcohol Dependence 111: 191-199.
66. Tao G, Datta S, He R, Nelson F, Wolinsky JS, et al. (2009) Deep gray matter atrophy in multiple sclerosis: A tensor based morphometry. J Neuro Sci 282: 39-46.
67. Yanovsky I, Leow AD, Lee S, Osher SJ, Thompson PM, (2009) Comparing registration methods for mapping brain change using tensor-based morphometry. Medical Image Analysis 13: 679-700.
68. Kovacevic N, Henderson JT, Chan E, Lifshitz N, Bishop J, et al. (2005) A Three-dimensional MRI Atlas of the Mouse Brain with Estimates of the Average and Variability. Cerebral Cortex 15: 639-645.
69. Ashburner J, Friston KJ, (2001) Why voxel-based morphometry should be used. Neuroimage 14: 1238-1243.
70. Chatham JC, Blackband SJ, (2001) Nuclear magnetic resonance spectroscopy and imaging in animal research. ILAR J 42: 189-208.
71. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM, (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81: 89-131.
72. Moffett JR, Namboodiri MAA, (1995) Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. Journal of Neurocytology 24: 409-433.
73. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, et al. (2001) Prefrontal neurons and the genetics of schizophrenia. Biological Psychiatry 50: 825-844.
74. Schuff N, Neylan TC, Fox-Bosetti S, Lenoci M, Samuelson KW, et al. (2008) Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. Psychiatry Res 162: 147-157.
75. Vielhaber S, Niessen HG, Debska-Vielhaber G, Kudin AP, Wellmer J, et al. (2008) Subfield-specific loss of hippocampal N-acetyl aspartate in temporal lobe epilepsy. Epilepsia 49: 40-50.
76. Steen RG, Hamer RM, Lieberman JA, (2005) Measurement of Brain Metabolites by 1H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. Neuropsychopharmacology 30: 1949-1962.
77. Hu YF, Caron M, Sieber-Blum M, (2009) Norepinephrine transport-mediated gene expression in noradrenergic neurogenesis. Bmc Genomics 10: 1-10.
78. Sieber-Blum M, Ren Z, (2000) Norepinephrine transporter expression and function in noradrenergic cell differentiations. Molecular and Cellular Biochemistry 212: 61-70.
79. Sanders JD, Happe HK, Bylund DB, Murrin LC, (2005) Development of the norepinephrine transporter in the rat CNS. Neuroscience 130: 107-117.
80. Xu F, Gainetdinov RR, Wetsel WC, Jones SR, Bohn LM, et al. (2000) Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neuroscience 3: 465-471.
81. Hall FS, Li XF, Sora I, Xu F, Caron M, et al. (2002) Cocaine mechanisms: Enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience 115: 153-161.
82. Rommelfanger KS, Weinshenker D, Miller GW, (2004) Reduced MPTP toxicity in noradrenaline transporter knockout mice. Journal of Neurochemistry 91: 1116-1124.
83. Pautler RG, Mongeau R, Jacobs RE, (2003) In vivo trans-synaptic tract tracing from the murine striatum and amygdala utilizing manganese enhanced MRI (MEMRI). Magnetic Resonance in Medicine 50: 33-39.
84. Van der Linden A, Van Camp N, Ramos-Cabrer P, Hoehn M, (2007) Current status of functional MRI on small animals: application to physiology, pathophysiology, and cognition. Nmr in Biomedicine 20: 522-545.
85. Silva AC, Bock NA, (2008) Manganese-Enhanced MRI: An Exceptional Tool in Translational Neuroimaging. Schizophr Bull 34: 595-604.
86. Pautler RG, Silva AC, Koretsky AP, (1998) In vivo neuronal tract tracing using manganese-enhanced magnetic resonance imaging. Magn Reson Med 40: 740-748.
87. Canals S, Beyerlein M, Keller AL, Murayama Y, Logothetis NK, (2008) Magnetic resonance imaging of cortical connectivity in vivo. Neuroimage 40: 458-472.
88. Van der Linden A, Van Camp N, Ramos-Cabrer P, Hoeh M, (2007) Current status of functional MRI on small animals: application to physiology, pathophysiology, and cognition. NMR in Biomedicine 20: 522-545.
89. Bonci A, Bernardi G, Grillner P, Mercuri NB, (2003) The dopamine-containing neuron: maestro or simple musician in the orchestra of addiction? Trends in Pharmacological Sciences 24: 172-177.
90. Robbins TW, Everitt BJ, (2002) Limbic-Striatal Memory Systems and Drug Addiction. Neurobiology of Learning and Memory 78: 625-636.
91. Nestler EJ, (2005) Is there a common molecular pathway for addiction? Nat Neurosci 8: 1445-1449.
92. Gobert A, Billiras R, Cistarelli L, Millan MJ, (2004) Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by [alpha]2-autoreceptors. Journal of Neuroscience Methods 140: 141-152.
93. Haenisch B, Boenisch H, (2011) Depression and antidepressants: Insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacology & Therapeutics 129: 352-368.
94. Moriya Y, Hall FS, Sora I (2013) The role of serotonin in the effects of psychostimulant drugs: Behavioral studies of addiction- and abuse-related phenotypes. In: Hall FS (ed.) In: Hall FS, editor. Serotonin: Biosynthesis, Regulation and Health Implications. New York: NOVA Science Publishers.
95. Sora I, Li B, Igari M, Hall FS, Ikeda K, (2010) Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Annals of the New York Academy of Sciences 1187: 218-246.
96. Kalueff AV, Olivier JDA, Nonkes LJP, Homberg JR, (2010) Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neuroscience and Biobehavioral Reviews 34: 373-386.
97. Haenisch B, Bilkei-Gorzo A, Caron MG, Boenisch H, (2009) Knockout of the norepinephrine transporter and pharmacologically diverse antidepressants prevent behavioral and brain neurotrophin alterations in two chronic stress models of depression. Journal of Neurochemistry 111: 403-416.
98. Robbins TW, Arnsten AFT, (2009) The Neuropsychopharmacology of Fronto-Executive Function: Monoaminergic Modulation. Annual Review of Neuroscience 32: 267-287.
99. Koob GF, Volkow ND, (2009) Neurocircuitry of Addiction. Neuropsychopharmacology 35: 217-238.
100. Paxinos G, Franklin K (2001) The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press. 296 p.
101. Gallagher JJ, Zhang X, Ziomek G, Jacobs RE, Bearer EL, (2012) Deficits in axonal transport in hippocampal-based circuitry and the visual pathway in APP knock-out animals witnessed by manganese enhanced MRI. NeuroImage 60: 1856-1866.
102. Hennig J, Nauerth A, Friedburg H, (1986) RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 3: 823-833.
103. Hasan KM, Basser PJ, Parker DL, Alexander AL, (2001) Analytical computation of the eigenvalues and eigenvectors in dt-mri. J Magn Reson 152: 41-47.
104. Shattuck DW, Leahy RM, (2001) Automated graph-based analysis and correction of cortical volume topology. IEEE Trans Med Imaging 20: 1167-1177.
105. Madabhushi A, Udupa JK, (2005) Interplay between intensity standardization and inhomogeneity correction in MR image processing. Medical Imaging, IEEE Transactions on 24: 561-576.
106. Bearer EL, Zhang X, Jacobs RE, (2007) Live imaging of neuronal connections by magnetic resonance: Robust transport in the hippocampal-septal memory circuit in a mouse model of Down syndrome. NeuroImage 37: 230-242.
107. Kochunov P, Lancaster JL, Thompson P, Woods R, Mazziotta J, et al. (2001) Regional spatial normalization: Toward an optimal target. Journal of Computer Assisted Tomography 25: 805-816.
108. Rex DE, Ma JQ, Toga AW, (2003) The LONI Pipeline Processing Environment. Neuroimage 19: 1033-1048.
109. Hof PR, Bloom FE, Belichenko PV, Celio MR (2000) Comparative Cytoarchitectonic Atlas of the C57bl/6 and 129/SV Mouse Brains. New York: Elsevier.
110. Dong HW (2008) Allen Reference Atlas - A Digital Color Brain Atlas of the C57Black/6J Male Mouse. Hoboken, NJ: John Wiley & Sons, Inc. 366 p.
111. Bottomley PA, (1987) Spatial localization in NMR spectroscopy in vivo. Annals of the New York Academy of Sciences 508: 333-348.
112. Tkáč I, Staručk Z, Choi I-Y, Gruetter R, (1999) In Vivo 1H NMR Spectroscopy of Rat Brain at 1ms Echo Time. Magnetic Resonance in Medicine 41: 649-656.
113. Gruetter R, (1993) Automatic, Localized Invivo Adjustment of All 1st-Order and 2nd-Order Shim Coils. Magnetic Resonance in Medicine 29: 804-811.
114. Ratiney H, Sdika M, Coenradie Y, Cavassila S, van Ormondt D, et al. (2005) Time-Domain Semi-Parametric Estimation Based on a Metabolite Basis Set. NMR Biomed 18: 1-13.
115. Naressi A, Couturier C, Devos J, Janssen M, Mangeat C, et al. (2001) Java-based graphical user interface for the MRUI quantitation package. Magma 12: 141-152.
116. Govindaraju V, Young K, Maudsley AA, (2000) Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed 13: 129-153.
117. Leow AD, Yanovsky I, Chiang MC, Lee AD, Klunder AD, et al. (2007) Statistical properties of Jacobian maps and the realization of unbiased large-deformation nonlinear image registration. Ieee Transactions on Medical Imaging 26: 822-832.
118. Dinov I, Lozev K, Petrosyan P, Liu Z, Eggert P, et al. (2010) Neuroimaging Study Designs, Computational Analyses and Data Provenance Using the LONI Pipeline. PLoS One 5: e13070.